药物诱导心力衰竭:使用FDA不良事件报告系统数据库的现实世界药监测研究
Youqi Huang1,2, Xiaowen Chen1,2, Mingyu Chen1,2
1Shengli Clinical College of Fujian Medical University, Department of Pharmacy, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Fuzhou, China.
Frontiers in pharmacology
|January 30, 2025
概括
这项研究确定了与心力衰竭 (HF) 和急性心力衰竭 (AHF) 相关的关键药物和药物类别. 早期监测至关重要,特别是在初始治疗阶段,以减轻风险.
科学领域:
- 药物监督 药物监督 药物监督
- 心脏病学 心脏病学
- 药品安全 药品安全
背景情况:
- 心力衰竭 (HF) 风险与某些药物类别有关,但具体风险尚不清楚.
- 了解药物诱导的高血压对于患者安全和有效的治疗策略至关重要.
研究的目的:
- 调查与心力衰竭 (HF) 和急性心力衰竭 (AHF) 相关的顶级药物和药物类别.
- 分析来自FDA不良事件报告系统 (FAERS) 的药物报告,以确定潜在的HF风险.
主要方法:
- 从2004年到2023年对药物不良事件的FAERS数据库进行了审查.
- 使用搜索术语"心力衰竭"和"急性心力衰竭"来识别相关病例.
- 分类和分析药物报告以确定与HF和AHF的关联.
主要成果:
- 报告了超过1700万次药物不良事件,其中240,050 (1.38%) 与HF和5,971与AHF有关.
- 确定了38种药物和13种药物类别可能导致HF,以及41种药物/19种类别与AHF相关.
- HF的中位发病时间为83天,AHF的中位发病时间为49天,这表明早期发病概况.
结论:
- 突出了与药物诱导的HF和AHF相关的关键药物和药物类.
- 强调早期风险评估和在初始治疗阶段密切监测的重要性.
- 为了解药物诱导的HF机制和未来研究提供了基础.
相关概念视频
Pharmacovigilance
770
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
770
Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
375
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
375
Heart Failure Drugs: β-Blockers
311
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
311
Heart Failure Drugs: Inotropic Agents
507
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
507
Heart Failure Drugs: Diuretics
338
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
338


